Monte Rosa Therapeutics (GLUE) Stock Forecast & Price Target

$7.67 -0.01 (-0.13%)

(As of 12/17/2024 ET)

Monte Rosa Therapeutics - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 3 Analyst Ratings

Sell
0

Hold
0

Buy
3

Based on 3 Wall Street analysts who have issued ratings for Monte Rosa Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 3 analysts, 3 have given a buy rating for GLUE.

Consensus Price Target

$16.00
108.60% Upside

According to the 3 analysts' twelve-month price targets for Monte Rosa Therapeutics, the average price target is $16.00. The highest price target for GLUE is $17.00, while the lowest price target for GLUE is $15.00. The average price target represents a forecasted upside of 108.60% from the current price of $7.67.

Get the Latest News and Ratings for GLUE and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Monte Rosa Therapeutics and its competitors.

GLUE Analyst Ratings Over Time

Type	Current Forecast 12/19/23 to 12/18/24	1 Month Ago 11/19/23 to 11/18/24	3 Months Ago 9/20/23 to 9/19/24	1 Year Ago 12/19/22 to 12/19/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	3 Buy rating(s)	3 Buy rating(s)	4 Buy rating(s)	2 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$16.00	$16.00	$13.75	$13.33
Forecasted Upside	108.60% Upside	112.20% Upside	120.00% Upside	138.10% Upside
Consensus Rating	Buy	Buy	Buy	Moderate Buy

Do this Before Elon’s Reveal on January 22nd (Ad)

Elon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.

I urge you to watch this video now.

GLUE Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

GLUE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Monte Rosa Therapeutics Stock vs. The Competition

Type	Monte Rosa Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.81	2.51
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	108.60% Upside	28,647.27% Upside	12.03% Upside
News Sentiment Rating	Neutral News See Recent GLUE News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
11/7/2024	Wedbush 4 of 5 stars	Reiterated Rating	Outperform	$15.00	+57.40%
8/12/2024	Wells Fargo & Company 3 of 5 stars	Lower Target	Overweight ➝ Overweight	$18.00 ➝ $17.00	+318.72%
6/28/2024	Piper Sandler 2 of 5 stars	Reiterated Rating	Overweight ➝ Overweight	$16.00 ➝ $16.00	+379.04%
10/19/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$31.00 ➝ $11.00	+240.56%
8/11/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$11.00	+64.67%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 03:36 AM ET.

GLUE Forecast - Frequently Asked Questions

: According to the research reports of 3 Wall Street equities research analysts, the average twelve-month stock price forecast for Monte Rosa Therapeutics is $16.00, with a high forecast of $17.00 and a low forecast of $15.00.
: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Monte Rosa Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" GLUE shares.
: According to analysts, Monte Rosa Therapeutics's stock has a predicted upside of 108.60% based on their 12-month stock forecasts.
: Monte Rosa Therapeutics has been rated by research analysts at Wedbush in the past 90 days.
: Analysts like Monte Rosa Therapeutics more than other "medical" companies. The consensus rating for Monte Rosa Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how GLUE compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Do this Before Elon’s Reveal on January 22nd (Ad)

I urge you to watch this video now.

This page (NASDAQ:GLUE) was last updated on 12/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Monte Rosa Therapeutics (GLUE) Stock Forecast & Price Target